Wall Street brokerages expect Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report earnings per share (EPS) of ($0.18) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Achillion Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.18) and the highest is ($0.17). Achillion Pharmaceuticals posted earnings of ($0.15) per share in the same quarter last year, which suggests a negative year over year growth rate of 20%. The business is scheduled to issue its next quarterly earnings report on Thursday, November 2nd.

On average, analysts expect that Achillion Pharmaceuticals will report full-year earnings of ($0.66) per share for the current fiscal year, with EPS estimates ranging from ($0.70) to ($0.57). For the next financial year, analysts forecast that the firm will post earnings of ($0.75) per share, with EPS estimates ranging from ($0.82) to ($0.61). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Achillion Pharmaceuticals.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). During the same quarter last year, the business posted ($0.14) earnings per share.

A number of research analysts recently weighed in on ACHN shares. BidaskClub raised shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Zacks Investment Research downgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Chardan Capital decreased their target price on shares of Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating for the company in a research report on Wednesday, August 9th. Maxim Group set a $7.00 target price on shares of Achillion Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 9th. Finally, Robert W. Baird downgraded shares of Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 target price for the company. in a research report on Thursday, August 10th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $6.50.

Several institutional investors and hedge funds have recently made changes to their positions in ACHN. Janus Henderson Group PLC bought a new position in shares of Achillion Pharmaceuticals in the 2nd quarter valued at about $20,778,000. Dimensional Fund Advisors LP grew its position in shares of Achillion Pharmaceuticals by 204.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,868,968 shares of the biopharmaceutical company’s stock valued at $8,579,000 after acquiring an additional 1,255,962 shares during the period. Senzar Asset Management LLC acquired a new stake in shares of Achillion Pharmaceuticals during the 2nd quarter worth about $4,966,000. EcoR1 Capital LLC acquired a new stake in shares of Achillion Pharmaceuticals during the 2nd quarter worth about $3,410,000. Finally, Vanguard Group Inc. lifted its stake in shares of Achillion Pharmaceuticals by 7.2% during the 1st quarter. Vanguard Group Inc. now owns 9,585,823 shares of the biopharmaceutical company’s stock worth $40,357,000 after buying an additional 646,415 shares during the last quarter. 74.12% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “-$0.18 Earnings Per Share Expected for Achillion Pharmaceuticals, Inc. (ACHN) This Quarter” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/09/18/0-18-earnings-per-share-expected-for-achillion-pharmaceuticals-inc-achn-this-quarter.html.

Achillion Pharmaceuticals (NASDAQ:ACHN) traded up 3.64% during midday trading on Friday, hitting $3.70. 2,388,457 shares of the company traded hands. The firm’s market capitalization is $506.02 million. Achillion Pharmaceuticals has a 12-month low of $3.15 and a 12-month high of $9.19. The stock’s 50-day moving average is $4.50 and its 200-day moving average is $4.20.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Stock Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.